Table 3.
Multivariable Analysis of COVID-19 Hospitalization in Patients With COVID-19 Breakthrough Infection
| Covariate | OR | 95% CI | P |
|---|---|---|---|
| Male sex | 1.14 | 0.76–1.70 | .539 |
| Age | 1.06 | 1.04–1.07 | <.001 |
| Health care worker | 0.15 | 0.05–0.50 | .002 |
| Smoking history | 0.92 | 0.60–1.40 | .685 |
| Chronic kidney disease | 1.19 | 0.64–2.19 | .583 |
| COPD | 1.05 | 0.63–1.77 | .848 |
| Diabetes mellitus | 1.37 | 0.87–2.15 | .171 |
| Cardiovascular disease | 3.02 | 1.55–5.89 | .001 |
| Hypertension | 0.86 | 0.54–1.37 | .521 |
| Immunocompromised | 2.57 | 1.70–3.90 | <.001 |
| Vaccine type | |||
| JNJ78436735 | 2.68 | 1.49–4.82 | <.001 |
| mRNA1273 | 1.82 | 1.23–2.71 | .003 |
| BNT162b2 | 0.436 | 0.303–0.626 | <.001 |
Odds ratio is presented with 95% CI. Significant P values are bolded. Number of observations in the original data set = 982. Number of observations used = 982.
Abbreviations: BNT162b2, Pfizer vaccine; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; JNJ78436735, Janssen vaccine; mRNA1273, Moderna vaccine; OR, odds ratio.